Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
1,6 miljoen voor 4 projecten naar zeldzame reuma
dec 2022 | JIA, Sclerodermie, SLE